Key clinical point: The first-in-class antiretroviral therapy islatravir (Merck) had promising efficacy in a phase 2b study including treatment-naive adults with HIV-1 infection.
Major finding: At 48 weeks, the proportions of patients with HIV-1 RNA less than 50 copies/mL was 89.7% for islatravir 0.25 mg and 83.9% for standard triple therapy.
Study details: An international, multicenter, 121-patient clinical trial including adults with HIV-1 infection naive to antiretroviral therapy.
Disclosures: The study was supported by Merck. Dr. Molina has been on the Merck advisory board and speaker’s bureau.
Molina J-M et al. IAS 2019, Abstract WEAB0402LB.